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cluded from the review. The studies included were categorised based on criteria
such as type of study, statistical methods for the learning effect, mathematical
framework for the economic analysis, year of publication, country and
intervention. RESULTS: The database search produced 930 articles. Only 2% of the
studies obtained were included given the above criteria. Of the excluded studies,
70% were excluded as they were not economic evaluations and 23% were excluded
as they did not formally present the learning effect. The remaining 7% were ex-
cluded based on other reasons: duplicates, non-English, non-human. The majority
of the studies are published after 2000. Of the included studies, the majority pre-
sented a learning effect related to health care costs. Two percent of the included
studies referred to utilities. Only one study synthesised cost and utilities.
CONCLUSIONS: Although the learning effect can have a notable impact on the
effectiveness of health care interventions, the economic evaluation literature on
the subject is very limited.
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OBJECTIVES: The Mutuelle Générale des Fonctionnaires et Agents de l’État de Côte
d’Ivoire (MUGEFCI) is a health mutual providing coverage services for its enrolees
(medical consultations, lab tests, medication expenses). This organization aims at
improving its current drug reimbursement process because of budgetary con-
straints. This study, therefore, aims at evaluating the feasibility of developing a
new formulary for the MUGEFCI in Côte d’Ivoire, by implementing a formulary-
listing framework specifically designed for under researched settings. METHODS:
The application of this framework, based on Multi-criteria Decision Analysis
(MCDA), consisted in four steps. First of all, we identified and weighted relevant
formulary listing criteria with their levels of variation. Then, we determined a set of
priority diagnostic/treatments to be assessed. Furthermore, scores were assigned
to these treatments according to their performance on the formulary listing criteria
levels. Last, we constructed a composite league table to rank the set of treatments
by priority order of reimbursement. A budget impact analysis was also conducted
to appraise the economic implications of the new composite drugs league table.
RESULTS: Policymakers in Côte d’Ivoire consider targeting cost-effectiveness and
severity of diseases as the most significant criteria for priority reimbursement of
drugs. This translates into a general preference for antimalarial, treatments for
asthma and antibiotics for urinary infection. Moreover, the results of the BIA sug-
gest that the new priority list of reimbursable drugs will be affordable when the real
economic impact of drugs per patient is under 66 US dollars. Over this threshold,
the MUGEFCI will have to select the reimbursable drugs according to their rank in
the priority list along with their respective budget impact per patient (cost per
patient). CONCLUSIONS: It is feasible to use MCDA to establish a formulary for
low-income countries. The application of this method is a step forward to trans-
parency in policymaking.
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OBJECTIVES: Robust and explicit methods to conduct systematic reviews of eco-
nomic evaluations are required to guarantee quality of reviews and their findings.
This is especially needed when assessing high resource-consuming topics such as
those related to the introduction of new imaging technologies. Our aim is to anal-
yse the methods for systematic reviews of economic evaluations of health
technologies. METHODS: We carried out a systematic review of methods for sys-
tematic reviews of economic evaluations by reading relevant parts of HTA meth-
odological manuals (“manuals”) and HTA reports from UK (“reports”) in English and
Italian at September 2010. RESULTS: We identified 27 manuals and 53 potential
reports. Among them, 6 and 40 contained relevant information respectively. None
of the 6 manuals described the criteria used for the identification or formulation of
the methods, or gave guidance on which method to follow. Among the 40 reports
included, 38/40 (95%) reports described search strategy and data bases used to
identify studies and inclusion criteria were presented in 21/40 (53%) reports. The
reports did not use a study quality assessment instrument were 9/40 (22.5%) while
20 different instruments were identified in the remaining reports. No report carried
out a quantitative synthesis of the data from the systematic review and 9/40 re-
ports (22.5%) clearly stated this. The reports that appear to include the data selec-
tively in their economic evaluation were 13/40 (32.5%). CONCLUSIONS: The ab-
sence of clear methodological guidance in manuals is reflected in the reports.
These show unclear rationale, methods and use of data from systematic reviews of
economic evaluations.
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OBJECTIVES: Many excellent health care databases are available in The Nether-
lands for (pharmaco-)epidemiologic research. However, in isolation these data re-
main scattered and have limitations with regard to sample sizes and/or detail of
the registered information.The objective of Mondriaan is to optimize access to en
linkage of routine health care databases in the The Netherlands for (pharmaco-
)epidemiologic research.METHODS:We have built an ICT infrastructure for collec-
tion and linkage of healthcare/research data in The Netherlands. To protect pri-
vacy, pseudonimisation and linkage is performed by a trusted third party (TTP). A
data catalogue on subject level has been developed to allow queries within the
integrated databases to support designing (pharmaco-) epidemiologic studies (incl.
sample size calculations, assessment of completeness of data). RESULTS: We are
able to routinely link all pharmacy records from the National Foundation of Phar-
maceutical Statistics (SFK) (n14,000,000) on a patient base to several routine
health care databases such as the Almere Health Care database (n200,000), the
Julius GP Network (n200,000), and the AGIS claims database (n1,200,000). Cur-
rently we are integrating several other databases in the The Netherlands.
CONCLUSIONS: The project will deliver a large-scale, high-quality data platform
for innovative (pharmaco-)epidemiologic research.
PRM15
THE OUTCOME OF ISPOR EUROPEAN AND INTERNATIONAL CONGRESSES
BETWEEN 2005-2009
Boncz I1, Sebestyen A2, Kriszbacher I1
1University of Pécs, Pécs, Hungary, 2Baranya County Health Insurance Fund, Pécs, Hungary
OBJECTIVES: Many of the former socialist countries of Central and Eastern Europe
(CCEE) joined to the European Union in 2004. The aim of this study is to analyse to
outcome of ISPOR European and international congresses between 2005-2009 with
a special respect to the activity of CCEE. METHODS: We analysed the abstracts
presented at the ISPOR European or International cogresses and published in the
Value in Health journal between 2005-2009. We performed a database analysis of
value in Health journal on the Web of Science (Thomson Reuters) electronic data-
base of scientific publications. Three indicators were selected: author’s country,
institution (university) and name. RESULTS: The top-10 most active countries were
(abstract/1 million population): Switzerland (48.3), Wales (31.0), Sweden (26.2),
Denmark (25.3), Belgium (25.0), The Netherlands (23.0), England (19.3), Canada
(18.3), Scotland (16.0) and Hungary (14.7). Furthermore Slovakia (8.2) was ranked
16th, Czech Republic (5.0) 24th, Poland (4.1) 26th and Serbia (3.3) 29th. The top-10
most active universities were (number of abstracts): Univ So Calif (140), Univ To-
ronto (107), Univ Washington (100), Ohio State Univ (98), Erasmus Univ & MC (94),
Univ Maryland (93), Univ Pécs Hungary (93), Univ York (92), Harvard Univ (89) and
McMaster Univ (76). Three more CCEE university were ranked: Med Univ Warsaw
from Poland (38), Corvinus Univ Budapest from Hungary (30) and Comenius Univ
from Slovakia (27). The most active 10 authors were (number of abstracts): Boncz, I
(Hungary, 96), Taieb, C (France, 83), Balkrishnan, R (USA, Ohio, 77), Sebestyén, A
(Hungary, 71), Valentine, WJ (Switzerland, 65), Mantovani, LG (Italy, 60), Caro, JJ
(USA, MA, 57), Annemans, L (Belgium, 54), Kriszbahcer, I (Hungary, 52), Rejas, J
(Spain, 50). CONCLUSIONS: Former socialist countries of Central and Eastern Eu-
rope (CCEE) showed a significant activity at ISPOR European and International con-
gresses.
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OBJECTIVES: The objective of this analysis is to compare several covariance struc-
tures which are used in the modeling of longitudinal data. METHODS: A PUBMED
search reveals is a steady increase in prospective observational studies over the
past five years. Repeated measures models are frequently used to analyze longitu-
dinal data. For the purpose of these comparisons, a series of longitudinal datasets
are simulated. In order to facilitate comparisons with applications to longitudinal
datasets involving utilities; the dependent variable in the simulation datasets is a
continuous variable restricted to the support interval [0, 1]. The predictor variables
include a set of categorical and continuous variables, including a time varying
covariate. Datasets with four different types of time dependence were compared
(no time trend, log time trend, linear trend, exponential trend). Models with the
following covariance structures were evaluated: compound symmetry, unstruc-
tured, autoregressive, heterogeneous autoregressive, variance components and
toeplitz. Model comparisons were based upon Akaike information criteria (AIC)
and the Bayesian information criteria (BIC). RESULTS: The preferred covariance
structures for the dataset without a time trend were heterogeneous autoregressive
(AIC) and unstructured (BIC). The preferred covariance structure for the log trend
dataset was unstructured (AIC and BIC). The preferred covariance structures for the
linear trend dataset were variance components (AIC) and heterogeneous autore-
gressive (BIC). The preferred covariance structure for the exponential trend dataset
was variance components (AIC and BIC). CONCLUSIONS: The unstructured cova-
riance matrix is often the default choice for the covariance matrix for longitudinal
models. This model has the least number of assumptions and allows for the mod-
eling of each patient individually. However, the unstructured covariance structure
requires the most degrees of freedom and in some cases the estimated covariance
matrix does not converge. In these cases, covariance structures such as variance
components and heterogeneous autoregressive may present attractive options.
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OBJECTIVES: The EQ-5D is the most used questionnaire to obtain utilities. Because
of its index ceiling effect, Tobit and CLAD-CQR (Censored Least Absolute Deviations
– Censored Quantile Regression) models are often used instead of Ordinal Least
Squares for its modelization. CLAD models are usually presented as a robust alter-
native to the Tobit misspecification problems in presence of heteroskedasticity.
The aim of this study is to evaluate the suitability of the CLAD-CQR models for the
estimation of utilities and QALYs (Quality-Adjusted Life Years), to evaluate the
impact of different chronic conditions in Catalan population’s health. METHODS:
The EQ-5D was interview-administered in the 2006 Catalan Health Interview Sur-
vey, a cross-sectional study of a representative sample of the non-institutionalised
general population (n15,926). As well as CLAD-CQR, Tobit model was adjusted to
assess utility losses associated with 15 chronic conditions. Goodness of fit was
assessed by cross-validation (Mean Square Error –MSE-, Mean Absolute Deviations
–MAD-). RESULTS: As ceiling effect was over 50%, CQR models on the 30 percentile
had to be applied instead of CLAD models on the median. CQR showed a slightly
worse fit to data (MSE0.084, MAD0.246) than Tobit (MSE0.068, MAD0.218).
The impact of the different chronic conditions measured in QALYs obtained from
the CQR was on average around 70% larger than the ones of the Tobit model.
CONCLUSIONS: Tobit and CLAD-CQR model latent quality of life, not anchored in
0death and 1perfect health. While Tobit allows an estimation of observed util-
ities and marginal effects, interpretable as QALYs, CQR do not in the case of right-
censoring. This leads to overestimation of effects and makes CLAD-CQR models
inappropriate for obtaining QALYs, just as the untransformed Tobit’s latent vari-
able. Moreover, the suitability of modelling percentiles differing from the median
should be discussed.
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OBJECTIVES: Regulators of medical technologies are facing increasing pressure to
make their deliberations concerning the benefits and risk more transparent. Both
benefits and risks are often measured via multiple competing outcomes. Hence,
MCDA models like the Analytic Hierarchy/Network Process are valuable tools in
quantifying decision trade-offs. The objective of this paper is to demonstrate the
use of MCDA models for benefit-risk assessment and the use of sensitivity analysis
to assess the impact of uncertainty and patient heterogeneity.METHODS:Using an
existing data set about anti-depressants we construct a decision model for use with
AHP weights, including clinical endpoints, adverse events and quality of life. AHP
priorities for the main criteria (benefits and risks) were obtained from the general
public (n15) using face–to-face interview. After base-case analysis of decision
trade-offs, three forms of sensitivity analysis for MCDA models were employed.
RESULTS: We applied three forms of sensitivity analysis, including 1) manual ad-
justment of criteria weights using a slider; 2) probabilistic sensitivity analysis (PSA)
of the criteria weights; and 3) PSA of the expected drug performance on each of the
criteria. Examples will be graphically presented and discussed. CONCLUSIONS:
One of the advantages of AHP/ANP is its ease of use. However, in order to make
judgments about benefits and risks decision makers, may wish to generalize to a
wider population and as well as to quantify decision trade-offs in subgroups of
patients. The methods employed provide this flexibility. However, the strategy
chosen should not be more complex than necessary to support the decision maker.
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OBJECTIVES: It is becoming increasingly common that early stage drug candidates
have potential applications in several therapy areas. This is especially prevalent
where several diseases share a similar aetiology. Areas such as immunology, on-
cology and metabolic disorders can have ailments that are characterised by differ-
ent physiological involvement but share a similar underlying cause. The objective
of this study was to model the impact of a multiple indication launch on drug
revenue over time, as well as develop a tool to enable launch strategy scenario
testing. METHODS: The attractiveness and potential NPV of each therapy area is
assessed using a combination of qualitative and quantitative methods. Therapy
areas are scored and ranked by defined metrics allowing the optimum therapy area
to be selected as the first launch indication. The assessment is repeated for the
remaining therapy areas to account for changes in pricing dynamics from the
initial launch indication, to generate the next most attractive therapy area and so
on. NPV for the drug is then calculated based on a trade-off between patient pop-
ulation size and pricing dynamics across indications. RESULTS: In general, the
larger patient populations translate into lower drug costs to meet with budget
impact thresholds. It is therefore vital for manufacturers to understand the optimal
trade-off between price and population size across indications in order to maxi-
mise the overall commercial potential of a drug. When different indications have
significantly differently sized patient populations, drug pricing becomes an issue.
The research concluded that if the correct strategy is employed, a drug launch
strategy can be optimised to generate the maximum possible revenue over the
greatest number of indications. CONCLUSIONS: Modeling changes in price and
population size during multiple-indication launches can be a vital tool in under-
standing total revenue potential of a new product, and optimal launch sequencing.
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OBJECTIVES:To compare three methods of measuring multimorbidity according to
the use of health resources (cost of care) in primary health care (PHC). METHODS:
Design: retrospective study using computerized medical records. Setting: thirteen
PHC teams in Catalonia (Spain). Participants: assigned patients requiring care in
2009. Main measurements: the socio-demographic variables, co-morbidity and
costs. Methods of comparison were: a) Combined Comorbidity Index (CCI): an index
itself was developed from the scores of acute and chronic episodes; b) Charlson
Index (ChI); and c) Adjusted Clinical Groups case-mix: resource use bands (RUB).
The cost model was constructed by differentiating between fixed (operational) and
variable costs. Statistical analysis: was developed 3 multiple lineal regression mod-
els to assess the explanatory power of each measure of co-morbidity were com-
pared from the of determination coefficient (R2), p0.05. RESULTS: A total fo
227,235 patients were included. Woman: 55.6%, average age was 44.1 years, mean
episodes/year: 4.5; average visits/patient/year: 8.1, the mean unit of cost was
€654.2. The CCI explained a R250.4%, the ChI a R229.2% and RUB a R239.7% of
the variability of the cost. The ICC is acceptable behaviour, albeit with low scores (1
to 3 points), showed no conclusive results. CONCLUSIONS: The CCI may be a sim-
ple method of predicting PHC costs in routine clinical practice. If confirmed, these
results will allow improvements in the comparison of the case-mix.
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OBJECTIVES: When evaluating healthcare interventions, decision-makers are in-
creasingly asked to consider multiple criteria to support their decision. The MCDA-
based EVIDEM framework was developed to support this process. It includes a
simple weight elicitation technique, designed to be easily applicable by a broad
range of users. The objective of this study was to compare the EVIDEM technique
with more traditional techniques. METHODS: An online questionnaire was devel-
oped comparing the EVIDEM technique with four alternative techniques including
AHP, best/worst scaling, ranking and point-allocation. A convenience sample of 60
Dutch and Canadian students were asked to fill out the questionnaires as if they
were sitting in an advisory committee for reimbursement/prioritization of health-
care interventions. They were asked to provide weights for 14 criteria using two
techniques, and to provide feedback on ease of use and clarity of concepts of the
different techniques. RESULTS: Results based on the first 30 responses show that
EVIDEM is easy to understand and takes little time to complete, three minutes on
average. Criteria weights derived using the EVIDEM technique and best/worst scal-
ing are divergent. Comparing the rank order of criteria respondents gave using
these two techniques; there is more resemblance in rank order of criteria weighted
with the EVIDEM technique. Compared to AHP/ranking/point-allocation, EVIDEM
takes less time to complete but is only preferred by 33% of decision-makers. AHP/
ranking and point allocation were often described as clearer and more reflective of
the respondents’ opinion. CONCLUSIONS: The simple technique is proposed as a
starting point for users wishing to adapt the EVIDEM framework to their own con-
text. Other techniques may be preferred and their impact on the MCDA value
estimate generated by applying the framework is being explored. This project is
part of a large collaborative work that includes developing and validating this
framework to facilitate sound and efficient MCDA-applications.
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OBJECTIVES: Personalized medicine (PM) takes into account that diagnostic and
therapeutic health technologies should be based on individual characteristics of
patients such as risk profile and treatment response. Health policy decisions under
constrained resources in PM require adequate evaluation methods that incorpo-
rate economic aspects and multiple characteristics (e.g., genotypes, blood mark-
ers). Microsimulation is a technique to evaluate health technologies, policies and
interventions based on individual characteristics. Our goal was to identify and
contrast different microsimulation approaches and discuss the applicability of
these approaches in the evaluation of PM. METHODS: We performed a review on
microsimulation and applications in social sciences, health care and politics. As-
sessment criteria include the modeling of patient characteristics/patient history/
prior events, the way events or transitions between health states are modeled, the
inclusion of life years/utilities/costs, open/closed cohort approach, and the way
time is modeled.RESULTS: Identified approaches range from state-transition mod-
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